Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $5.3 million.

  • Xeris Biopharma Holdings' Other Non-Current Assets fell 231.49% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 231.49%. This contributed to the annual value of $5.4 million for FY2024, which is 1909.69% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Other Non-Current Assets stood at $5.3 million, which was down 231.49% from $5.1 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Other Non-Current Assets registered a high of $5.5 million during Q2 2024, and its lowest value of $211000.0 during Q3 2021.
  • Moreover, its 5-year median value for Other Non-Current Assets was $4.7 million (2022), whereas its average is $4.0 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first surged by 92843.6% in 2022, then plummeted by 786.31% in 2025.
  • Xeris Biopharma Holdings' Other Non-Current Assets (Quarter) stood at $829000.0 in 2021, then soared by 470.57% to $4.7 million in 2022, then dropped by 4.02% to $4.5 million in 2023, then rose by 19.1% to $5.4 million in 2024, then fell by 1.66% to $5.3 million in 2025.
  • Its Other Non-Current Assets stands at $5.3 million for Q3 2025, versus $5.1 million for Q2 2025 and $5.1 million for Q1 2025.